FDA should consider drug-therapy regimens | Science

In his In Depth story “What’s next for psychedelics after MDMA rejection?” (16 August, p. 702), K. Kupferschmidt describes how the US Food & Drug Administration (FDA) turned down the application of a combination of 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy, and psychotherapy for posttraumatic stress disorder…
Read More